Rakovina Therapeutics Announces Strategic Pivot to AI
Rakovina Therapeutics Announces Strategic Pivot to AI
Company Leveraging Deep Docking AI Drug Discovery Platform
公司利用深度对接人工智能药物发现平台
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), ("Rakovina" or the "Company"), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce a strategic evolution in its business model that will place the Company at the forefront of artificial intelligence-driven (AI) precision medicine for cancer drug development research.
不列颠哥伦比亚省温哥华,2024年3月27日(GLOBE NEWSWIRE)——致力于通过开发新型DNA损伤反应抑制剂疗法改善癌症患者生活的生物制药公司Rakovina Therapeutics Inc.(多伦多证券交易所股票代码:RKV)(“Rakovina” 或 “公司”)很高兴地宣布其商业模式的战略演变,这将使公司走在最前沿人工智能驱动(AI)精准医学,用于癌症药物开发研究。
The Company has entered into a collaboration agreement ("Agreement") with Dr. Artem Cherkasov granting Rakovina exclusive access to the proprietary Deep Docking (trademarked) AI Platform for DNA-damage response targets. Dr. Cherkasov is a professor at the University of British Columbia (UBC) and a senior scientist at the Vancouver Prostate Centre and was appointed to the Company's scientific advisory board in November 2023.
该公司已与Artem Cherkasov博士签订了合作协议(“协议”),授予Rakovina独家使用专有的Deep Docking(商标)人工智能平台,用于DNA损伤响应目标。切尔卡索夫博士是不列颠哥伦比亚大学(UBC)的教授,也是温哥华前列腺中心的资深科学家,并于2023年11月被任命为公司科学顾问委员会成员。
Using the Deep Docking platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures to evaluate their potential as targeted cancer drugs. The company then validates the activity using its established R&D infrastructure. This approach is innovative to developing new drug therapies that target DNA-damage response-related vulnerabilities that are common in many types of cancer.
使用由先进的人工智能算法提供支持的深度对接平台,Rakovina可以快速分析数十亿个分子结构,以评估其作为靶向抗癌药物的潜力。然后,该公司使用其已建立的研发基础设施对活动进行验证。这种方法在开发针对许多类型癌症中常见的DNA损伤反应相关漏洞的新药物疗法方面具有创新性。
"This strategic change of business for us is a significant step forward in Rakovina's mission," said Executive Chair Jeffrey Bacha. "The Deep Docking AI Platform will rapidly screen billions of drug candidates against validated DNA-damage response targets, predicting safety, efficacy and pharmaceutical properties. We then validate their activity in our confirmatory assays and advance the most promising drug candidates through human clinical trials and pharmaceutical partnerships."
执行主席杰弗里·巴查说:“对我们来说,这种业务战略变革是拉科维纳使命向前迈出的重要一步。”“Deep Docking AI 平台将根据经过验证的DNA损伤反应靶标快速筛选数十亿候选药物,预测安全性、有效性和药物特性。然后,我们在确认性分析中验证其活性,并通过人体临床试验和药物合作推进最有前途的候选药物。”
"Under the leadership of Rakovina's Chief Scientific Officer Dr. Mads Daugaard, we are honoured to leverage the expertise of Dr. Cherkasov and the research infrastructure already established in collaboration with UBC. We look forward to sharing additional details with our shareholders on our upcoming conference call," added Bacha.
“在拉科维纳首席科学官马兹·道加德博士的领导下,我们很荣幸能够利用切尔卡索夫博士的专业知识以及与UBC合作建立的研究基础设施。我们期待在即将举行的电话会议上与股东分享更多细节,” 巴查补充说。
Founded in 2021, Rakovina's mission has always been to transform and prolong the lives of individuals battling cancer. The DNA-damage response is a crucial mechanism for maintaining genomic integrity, and defects in these pathways contribute to the development and progression of many cancers. Rakovina recognizes the urgency of addressing this issue and is committed to developing targeted therapies to overcome resistance to conventional treatments.
Rakovina成立于2021年,其使命一直是改变和延长与癌症作斗争的人的寿命。DNA损伤反应是维持基因组完整性的关键机制,这些途径的缺陷会导致许多癌症的发展和进展。Rakovina意识到解决这个问题的紧迫性,并致力于开发靶向疗法以克服对传统疗法的耐药性。
Rakovina Strategic Information Conference Call
拉科维纳战略信息电话会议
The Rakovina leadership team and members of the scientific team will be hosting a conference call to provide additional information about the company's new strategic direction and industry insights.
Rakovina领导团队和科学团队成员将举行电话会议,以提供有关公司新战略方向和行业见解的更多信息。
Conference Call Details: | |
Date: | April 3, 2024 |
Time: | 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) |
Link: |
电话会议详情: | |
日期: | 2024年4月3日 |
时间: | 太平洋时间上午 10:00(东部时间下午 1:00) |
链接: |
About Rakovina Therapeutics Inc.
关于 Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies.
Rakovina Therapeutics Inc.专注于开发基于新型DNA损伤反应技术的新型癌症治疗方法。该公司已经建立了一条新型DNA损伤反应抑制剂产品线,目标是将一种或多种候选药物推进人体临床试验,并获得加拿大卫生部、美国食品药品监督管理局和类似国际监管机构的癌症新疗法的上市许可。
Led by a seasoned team of industry experts, Rakovina is well-positioned to drive innovation in the field of oncology. Bacha brings over 25 years of healthcare and life science experience, while Dr. Daugaard, brings decades of experience in DNA damage responses and translational cancer research.
在经验丰富的行业专家团队的领导下,Rakovina完全有能力推动肿瘤学领域的创新。Bacha 拥有超过 25 年的医疗保健和生命科学经验,而 Daugaard 博士则在 DNA 损伤反应和转化癌症研究方面拥有数十年的经验。
Further information may be found at .
更多信息可以在以下网址找到。
The Company's Scientific Advisory Board, chaired by Dr. Dennis Brown, is composed of esteemed scientists and researchers in the fields of science and cancer research. Members are Dr. Cherkasov, Dr. Petra Hamerlik, Dr. Leonard Post, and Dr. Wang Shen, who bring invaluable expertise to Rakovina Therapeutics' research and development efforts.
公司的科学顾问委员会由丹尼斯·布朗博士担任主席,由科学和癌症研究领域的受人尊敬的科学家和研究人员组成。成员包括切尔卡索夫博士、佩特拉·哈默利克博士、伦纳德·波斯特博士和王申博士,他们为Rakovina Therapeutics的研发工作带来了宝贵的专业知识。
For Additional Information Contact:
Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: info@rakovinatherapeutics.com
如需更多信息,请联系:
Rakovina Therapeutics Inc.
大卫海曼
首席财务官
电子邮件:info@rakovinatherapeutics.com
Investor Relations Contact:
ir@rakovinatherapeutics.com
投资者关系联系人:
ir@rakovinatherapeutics.com
Media Contact:
media@rakovinatherapeutics.com
媒体联系人:
media@rakovinatherapeutics.com
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所既未批准也未批准本新闻稿的内容。多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
Notice of Forward-Looking Statements
前瞻性陈述通知
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may","could","would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company.
本新闻稿包括有关公司及其各自业务的前瞻性陈述,其中可能包括但不限于与公司拟议业务计划有关的陈述和其他陈述。通常,但并非总是如此,前瞻性陈述可以通过使用 “计划”、“预期”、“预期”、“计划”、“打算”、“考虑”、“预期”、“相信”、“提议” 等词语或此类词语和短语的变体(包括负面变体)来识别,或者声明某些行动、事件或结果 “可能”、“可能” 或 “将” 被采取、发生或实现。此类声明基于公司管理层当前的预期。
The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at .
本新闻稿中讨论的前瞻性事件和情况可能不会在某些特定日期之前发生,也可能根本不会发生,并且由于影响公司的已知和未知风险因素和不确定性,包括医疗器械行业的风险、经济因素、监管因素、总体股票市场以及与增长和竞争相关的风险,可能会有重大差异。尽管公司试图确定可能导致实际行动、事件或结果与前瞻性陈述中描述的重大差异的重要因素,但可能还有其他因素导致行动、事件或结果与预期、估计或预期的不同。任何前瞻性陈述都无法保证。除非适用的证券法要求,否则前瞻性陈述仅代表其发布之日,并且公司没有义务公开更新或修改任何前瞻性陈述,无论是由于新信息、未来事件还是其他原因。请读者参阅公司在SEDAR上提交的最新文件,以更全面地讨论所有适用的风险因素及其潜在影响,其副本可通过公司的个人资料页面访问,网址为。